Five-Year Outcomes for Patients With RVOT Dysfunction Treated With the SAPIEN 3 Transcatheter Heart Valve: A Pooled Analysis From the COMPASSION S3 Trial

Key Result

The SAPIEN 3 transcatheter heart valve was evaluated for five-year outcomes in patients with right ventricular outflow tract dysfunction in the COMPASSION S3 trial.

Key Points

• The analysis aims to evaluate the five-year outcomes for patients with RVOT dysfunction following treatment with the SAPIEN 3 transcatheter heart valve.
• Conducted a pooled analysis of data from the COMPASSION S3 trial.
• Focused on patients experiencing RVOT (right ventricular outflow tract) dysfunction.
• Utilized statistical methods to analyze long-term outcomes.
• Demonstrated significant improvement in hemodynamic parameters post-treatment.
• Showed durability of the SAPIEN 3 valve over five years.
• Reported low rates of mortality and valve-related complications.